TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›PHGE›Financials
Annual statements · SEC XBRL · FY2018 – FY2025

BiomX Inc. (PHGE) financials

Income statement

BiomX Inc. (PHGE) income statement, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$12.5M-$22.2M-$30.3M-$35.5M-$27.2M-$25.3M-$44.5M-$41.5M
Net income-$12.7M-$20.6M-$30.1M-$36.2M-$28.3M-$26.2M-$17.7M-$36.2M
EPS (diluted)$7.62$3.66$1.30$1.39$0.95$5.10$58.31$22.19

Cash flow

BiomX Inc. (PHGE) cash flow, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$11.3M-$17.6M-$24.4M-$27.6M-$29.1M-$21.3M-$37.0M-$26.4M
Capital expenditures$137K$1.31M$1.01M$3.68M$112K$50.0K$30.0K$2.00K
Free cash flow-$11.4M-$18.9M-$25.5M-$31.3M-$29.2M-$21.3M-$37.0M-$26.4M

Balance sheet

BiomX Inc. (PHGE) balance sheet, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$8.60M$72.3M$36.5M$62.1M$31.3M$14.9M$16.9M$4.36M
Total assets$45.3M$92.1M$70.4M$78.0M$45.5M$25.0M$43.2M$5.78M
Total liabilities$41.0K$871K——————
Long-term debt———$14.4M$10.6M$5.40M——
Shareholders' equity$42.8M$84.5M$57.5M$47.5M$21.0M$3.08M$24.1M-$1.30M
Retained earnings-$1.02K$346K——-$137M-$163M-$181M-$217M
Shares (wtd avg diluted)2.31M22.9M23.3M26.0M29.9M5.13M758K1.63M

Every figure is extracted from BiomX Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is BiomX Inc.'s free cash flow?
-$26.4M in FY2025 (operating cash flow -$26.4M minus $2.00K of capital expenditures), from the SEC cash-flow statement.
Does PHGE pay a dividend?
BiomX Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full PHGE analysis — verdict, score & filings →Is PHGE a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.